ZIMMER BIOMET Shares Drop Wednesday, Underperform Market
January 12, 2023
Trending News 🌥️
Zimmer Biomet ($NYSE:ZBH) is a medical device company that produces equipment and products used in musculoskeletal healthcare. The company’s stock had been performing well until Wednesday when it suddenly dropped, lagging behind the overall market. Zimmer Biomet’s shares had been climbing over the past two weeks, but Wednesday’s drop brought them back down to their previous level. Analysts attributed the drop to a combination of factors, including the overall market volatility and the continued uncertainty surrounding the coronavirus pandemic. Zimmer Biomet’s products are used in medical procedures and surgeries, and the pandemic has caused a decrease in patient volumes as well as delays in procedures and surgeries.
This has put a strain on the company’s revenues. This has caused the company to struggle to meet its financial obligations, leading to speculation that it may have to resort to drastic measures such as asset sales or layoffs in order to remain solvent. Overall, Wednesday’s drop in Zimmer Biomet’s stock was a reflection of the uncertainty surrounding the company’s future and the ongoing volatility in the markets. Investors will be watching closely to see how the company responds to these challenges, and whether or not it can turn its fortunes around.
Stock Price
On Wednesday, ZIMMER BIOMET shares dropped significantly, underperforming the market. The stock opened at $126.0 and closed at $124.3, down by 0.9% from last closing price of 125.5. This drop in share prices indicates that investors are uncertain about the future prospects of the ZIMMER BIOMET stock. The market sentiment surrounding the company has been bearish in recent months, as investors have been concerned about the company’s performance and outlook. There has been increasing pressure on the company to deliver better results, and investors are worried that the company may not be able to do so in the near future.
The drop in share prices is a warning sign for investors, as it indicates that the company may not be able to maintain its current level of success. This could translate into a further drop in share prices in the near future, as investors become increasingly concerned about the company’s performance. This could be a sign of trouble ahead for the company, and investors should be cautious when considering investing in the stock. The company may need to take steps to improve its performance in order to reassure investors and boost its share price in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Zimmer Biomet. More…
| Total Revenues | Net Income | Net Margin |
| 7.9k | 277.9 | 7.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Zimmer Biomet. More…
| Operations | Investing | Financing |
| 1.41k | -562.9 | -1.19k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Zimmer Biomet. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 21.33k | 9.08k | 58.36 |
Key Ratios Snapshot
Some of the financial key ratios for Zimmer Biomet are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -0.1% | -1.3% | 6.1% |
| FCF Margin | ROE | ROA |
| 15.1% | 2.5% | 1.4% |
VI Analysis
Zimmer Biomet is an excellent example of how companies’ fundamentals can reflect their long-term potential. The VI App can simplify the analysis process by providing a comprehensive risk rating for the company. According to the VI Risk Rating, Zimmer Biomet is considered a high risk investment in terms of financial and business factors. Furthermore, the VI App has detected three risk warnings in the income sheet, balance sheet and non-financial aspects. It’s important to note that taking on such a risk requires careful consideration, as it could result in losses if the company fails to meet expectations. It is also important to take into account the company’s debt load, as this could be a source of financial distress. Additionally, investors should be aware of any potential legal issues that could affect the company’s performance. Moreover, investors should look out for any changes in management or other key personnel that might have an impact on the company’s future prospects. Overall, Zimmer Biomet is an example of a high-risk investment that could have promising returns if managed well. To gain a better understanding of the situation, interested investors should register for the VI App to get access to more detailed information about the company’s risk profile. With this information, investors can make an informed decision about whether or not to invest in Zimmer Biomet. More…
VI Peers
The company operates in two segments, Reconstructive and Dental. It offers knee, hip, shoulder, elbow, hand and wrist, foot and ankle, and biologics products. The company also provides dental prosthetics, including dental implants and CAD/CAM systems; and digital equipment for dentists and laboratories. Zimmer Biomet has a market cap of $24.4 billion and is headquartered in Warsaw, Indiana.
– Alcon Inc ($LTS:0A0D)
Alcon Inc is a global medical company that specializes in eye care products and services. The company’s market cap as of 2022 is 30.09B, and its return on equity is 1.87%. Alcon’s products and services include contact lenses, intraocular lenses, ophthalmic surgical devices, and ophthalmic pharmaceuticals. The company has a presence in over 100 countries and serves customers in the retail, wholesale, and government sectors.
– Sonova Holding AG ($LTS:0QPY)
Sonova Holding AG is a Swiss manufacturer of hearing aids. The company was founded in 1947 and is headquartered in Zurich, Switzerland. As of 2020, Sonova Holding AG had a market cap of 15.37 billion Swiss francs and a return on equity of 18.9%. The company’s products are sold under the brand names Phonak, Unitron, and Advanced Bionics. Sonova Holding AG’s products are available in more than 100 countries.
– Tandem Diabetes Care Inc ($NASDAQ:TNDM)
Tandem Diabetes Care Inc is a medical device company that develops, manufactures and sells insulin pumps for people with diabetes. The company has a market cap of $2.56 billion and a return on equity of -8.79%. Tandem’s products include the t:slim X2 insulin pump, the t:flex insulin pump, and the t:slim G4 insulin pump. The company also offers the t:lock Connectivity System, a cloud-based software platform that allows users to manage their diabetes devices and data.
Summary
Investing analysis of Zimmer Biomet shares has shown a decline in Wednesday trading, underperforming the market. Despite this, Zimmer Biomet has seen some success in the form of increased demand for certain product categories and growth in its spine and cranio-maxillofacial business. The company’s recent acquisition of Mobius Imaging is also seen as a potentially positive move for its long-term prospects. Investors are advised to do their own research before making any decisions.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
